Bullous pemphigoid disease is an autoimmune disorder affecting the skin and mucosal membranes, characterized by the formation of large fluid-filled blisters or bullae. It typically affects the elderly and is caused due to the presence of autoantibodies against components of the dermal-epidermal junction of the skin. The currently available bullous pemphigoid disease therapeutics include corticosteroids, immunosuppressants, immunomodulators, and biologics that help manage the condition by controlling the immune response.
The bullous pemphigoid market is estimated to be valued at USD 1.4 Bn in 2024 and is expected to reach USD 2.8 Bn by 2031, growing at a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.
Key Takeaways
Key players operating in the Bullous Pemphigoid Market are Pfizer Inc., Glenmark Pharmaceuticals, Novartis AG, Argenx SE, Sanofi S.A., F. Hoffmann-La Roche Ltd., Merck & Co., Inc., and InflaRx N.V.
Some key opportunities in the Bullous Pemphigoid Market include the development of novel biologics and immunomodulators with improved efficacy and safety profiles. Ongoing research for identifying the pathophysiology of bullous pemphigoid disease may also lead to the development of new targeted treatment approaches.
Geographic expansion into emerging markets and focus on specialty drugs present lucrative growth prospects for bullous pemphigoid disease treatment manufacturers.
Market drivers
The rising prevalence of bullous pemphigoid disease, especially in the elderly population, is a key factor fueling market growth. According to estimates, the prevalence of bullous pemphigoid ranges between 10 to 30 cases per million people worldwide. Improving diagnosis and awareness levels are also contributing to the increasing patient base. Furthermore, the lack of an effective cure is prompting continuous research into advanced treatment modalities, providing a strong impetus to market revenues.
PEST Analysis
Political: The regulations set by government authorities regarding genetic research and new drugs can impact the Bullous Pemphigoid Market.
Economic: Changes in the overall economic conditions of regions with high bullous pemphigoid prevalence can increase or decrease the healthcare expenditures for its treatment.
Social: Growing geriatric population prone to autoimmune disorders is a key factor augmenting the social need for effective bullous pemphigoid treatment options.
Technological: Advancements in genetic understanding of bullous pemphigoid pathogenesis and development of novel biologics with selective mechanisms of action are expanding technological possibilities in this market.
Geographical Regions of Concentration
Currently, North America accounts for the largest share of the global Bullous Pemphigoid Market in terms of value. This is attributed to factors such as high healthcare expenditure, widespread medical insurance coverage, growing geriatric demographics susceptible to bullous pemphigoid in the US and Canada. Europe is another major revenue generator for players in this domain given the large patient volumes and continually improving medical technologies across different countries.
Fastest Growing Regional Market
The Bullous Pemphigoid Market is anticipated to witness the fastest growth in Asia Pacific during the forecast period. This can be accredited to rising medical needs of aging populations, improving access to sophisticated medications, and increasing investments by international companies looking to tap emerging opportunities in nations like China, India and Japan.
Get This Report in Japanese Language: 水疱性類天疱瘡市場
Get This Report in Korean Language: 수포성 천포창 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)
